Genvoya approved to treat HIV-1 infection

Genvoya contains a new form of tenofovir that delivers lower amounts of the drug into the bloodstream, but higher amounts wtithin the cells where HIV-1 replicates.
Genvoya contains a new form of tenofovir that delivers lower amounts of the drug into the bloodstream, but higher amounts wtithin the cells where HIV-1 replicates.

HealthDay News — A new treatment for HIV has been approved by the U.S. Food and Drug Administration. Genvoya – a tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide – can be used to treat HIV-1 infection in adults and children 12 and older weighing at least 77 pounds.

Genvoya – made by California-based Gilead Sciences – contains a new form of tenofovir not previously approved by the FDA. This new form of tenofovir delivers lower amounts of drug into the bloodstream, but higher amounts within cells where HIV-1 replicates. The approval is based on four clinical trials that included a total of 3,171 patients. The results of the trials showed Genvoya to be effective in reducing viral loads and comparable to other treatments, the FDA said.

The most common side effect associated with Genvoya is nausea. The product carries a Boxed Warning about the possible risk of a build-up of lactic acid in the blood and severe liver problems, both of which can be fatal. The warning also states that Genvoya is not approved to treat chronic hepatitis B infection.

"Today's approval of a fixed-dose combination containing a new form of tenofovir provides another effective, once-daily complete regimen for patients with HIV-1 infection," Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Reference

  1. FDA approves new treatment for HIV [news release]. Silver Spring, MD: The U.S. Food and Drug Administration; November 5, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471300.htm. Accessed November 9, 2015.
Loading links....
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters